AR072336A1 - Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion - Google Patents
Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacionInfo
- Publication number
- AR072336A1 AR072336A1 ARP080105365A ARP080105365A AR072336A1 AR 072336 A1 AR072336 A1 AR 072336A1 AR P080105365 A ARP080105365 A AR P080105365A AR P080105365 A ARP080105365 A AR P080105365A AR 072336 A1 AR072336 A1 AR 072336A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compound
- formula
- independently
- procedure
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/173845—Amine and quaternary ammonium
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1), caracterizado porque R1 es -ORa o -C(O)NRbRc; R2, R3 y R4 son, cada uno en forma independiente, alquilo C1-3; R5 se selecciona de alquilo C1-6, fenilo, ciclohexilo, -(CH2)1-3-ciclohexilo y -(CH2)1-3-fenilo; Ra, Rb y Rc son, cada uno en forma independiente, hidrogeno o alquilo C1-3; y R6 es hidrogeno o alquilo C1-3; y porque los sustituyentes en los centros quirales marcados con asteriscos se presentan en la configuracion trans; o una de sus sales farmacéuticamente aceptables. Reivindicacion 13: Una composicion farmacéutica que comprende el compuesto de cualquiera de las reivindicaciones 1 a 12 y un portador farmacéuticamente aceptable. Reivindicacion 15: Un procedimiento para elaborar un compuesto de la formula (1), o una de sus sales, caracterizado porque R1 es -ORa o -C(O)NRbRc; R2, R3 y R4 son, cada uno en forma independiente, alquilo C1-3; R5 se selecciona de alquilo C1-6, fenilo, ciclohexilo, -(CH2)1-3-ciclohexilo y -(CH2)1-3-fenilo; Ra, Rb y Rc son, cada uno en forma independiente, hidrogeno o alquilo C1-3; y R6 es hidrogeno o alquilo C1-3; y porque los sustituyentes en los centros quirales marcados con asteriscos se presentan en la configuracion trans; el procedimiento comprende: (a) hacer reaccionar un compuesto de la formula (2) con un compuesto de la formula (3), caracterizado porque R6 es alquilo C1-3; y (b) cuando R6 es hidrogeno, poner en contacto el producto del paso (a) con un exceso de base para proporcionar un compuesto de formula (1) o una de sus sales. Reivindicacion 16: Un compuesto de formula (4) o una de sus sales de bromhidrato, caracterizado porque R2 y R3 son, cada uno en forma independiente, alquilo C1-3, y los sustituyentes en los centros quirales marcados con asteriscos están en la configuracion trans. Reivindicacion 17: Un procedimiento para elaborar una sal de bromhidrato de un compuesto de la formula (4) en forma solida, caracterizado porque R2 y R3 son, cada uno en forma independiente, alquilo C1-3, y los sustituyentes en los centros quirales marcados con asteriscos se presentan en la configuracion trans; el procedimiento comprende: (a) hacer reaccionar una mezcla racémica de un compuesto de formula (5) y un compuesto que tiene la estereoquímica opuesta en los centros quirales, donde P1 es alquilo C1-3, con bromuro de hidrogeno para formar la sal de bromhidrato del compuesto de formula (4); y (b) aislar la sal de bromhidrato del compuesto de la formula (4) en forma solida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US722007P | 2007-12-11 | 2007-12-11 | |
| US4921908P | 2008-04-30 | 2008-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072336A1 true AR072336A1 (es) | 2010-08-25 |
Family
ID=40521484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105365A AR072336A1 (es) | 2007-12-11 | 2008-12-10 | Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8106232B2 (es) |
| EP (1) | EP2231585B1 (es) |
| JP (1) | JP5403762B2 (es) |
| KR (1) | KR101610165B1 (es) |
| CN (1) | CN101896455B (es) |
| AR (1) | AR072336A1 (es) |
| AU (1) | AU2008335210B2 (es) |
| BR (1) | BRPI0821611A8 (es) |
| CA (1) | CA2707981C (es) |
| CL (1) | CL2008003672A1 (es) |
| CO (1) | CO6300937A2 (es) |
| ES (1) | ES2402749T3 (es) |
| IL (1) | IL205949A (es) |
| MY (1) | MY149973A (es) |
| NZ (1) | NZ586048A (es) |
| RU (1) | RU2482107C2 (es) |
| TW (1) | TWI412360B (es) |
| WO (1) | WO2009076408A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP2439196A1 (en) | 2006-03-29 | 2012-04-11 | The Regents of The University of California | Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder |
| CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
| WO2009076399A2 (en) | 2007-12-11 | 2009-06-18 | Theravance, Inc. | Aminotetralin compounds as mu opioid receptor antagonists |
| WO2009124022A1 (en) | 2008-04-01 | 2009-10-08 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| AU2009324709B2 (en) * | 2008-12-10 | 2015-07-16 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a 3-carboxypropyl-aminotetralin compound |
| JP5797655B2 (ja) * | 2009-09-18 | 2015-10-21 | アドラー・コーポレーション | 消化管障害のためのオピオイド受容体アンタゴニストの使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100195656B1 (ko) * | 1989-05-31 | 1999-06-15 | 로버트 에이.아미테이지 | 치료학적으로 유용한 2-아미노테트랄린 유도체 |
| WO2000037438A1 (en) * | 1998-12-22 | 2000-06-29 | Astrazeneca Ab | Novel thio-aminotetralin compounds useful in pain management |
| US6844368B1 (en) * | 1998-12-22 | 2005-01-18 | Edward Roberts | Compounds useful in pain management |
| US6498196B1 (en) * | 1998-12-22 | 2002-12-24 | Edward Roberts | Compounds useful in pain management |
| WO2000037426A1 (en) * | 1998-12-22 | 2000-06-29 | Astrazeneca Ab | Novel oxo-aminotetralin compounds useful in pain management |
| US6231594B1 (en) * | 1999-08-11 | 2001-05-15 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
| MX2009004965A (es) | 2006-11-07 | 2009-06-05 | Nektar Therapeutics Al Corp | Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides. |
| WO2009076399A2 (en) | 2007-12-11 | 2009-06-18 | Theravance, Inc. | Aminotetralin compounds as mu opioid receptor antagonists |
| WO2009124022A1 (en) | 2008-04-01 | 2009-10-08 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| AU2009324709B2 (en) | 2008-12-10 | 2015-07-16 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a 3-carboxypropyl-aminotetralin compound |
-
2008
- 2008-12-10 WO PCT/US2008/086171 patent/WO2009076408A2/en active Application Filing
- 2008-12-10 BR BRPI0821611A patent/BRPI0821611A8/pt not_active Application Discontinuation
- 2008-12-10 KR KR1020107014774A patent/KR101610165B1/ko active IP Right Grant
- 2008-12-10 EP EP08859864A patent/EP2231585B1/en active Active
- 2008-12-10 US US12/331,659 patent/US8106232B2/en not_active Expired - Fee Related
- 2008-12-10 CL CL2008003672A patent/CL2008003672A1/es unknown
- 2008-12-10 ES ES08859864T patent/ES2402749T3/es active Active
- 2008-12-10 MY MYPI2010002437A patent/MY149973A/en unknown
- 2008-12-10 CN CN200880119873.7A patent/CN101896455B/zh not_active Expired - Fee Related
- 2008-12-10 CA CA2707981A patent/CA2707981C/en active Active
- 2008-12-10 RU RU2010128542/04A patent/RU2482107C2/ru active
- 2008-12-10 JP JP2010538112A patent/JP5403762B2/ja not_active Expired - Fee Related
- 2008-12-10 NZ NZ586048A patent/NZ586048A/en not_active IP Right Cessation
- 2008-12-10 AR ARP080105365A patent/AR072336A1/es unknown
- 2008-12-10 TW TW097148045A patent/TWI412360B/zh not_active IP Right Cessation
- 2008-12-10 AU AU2008335210A patent/AU2008335210B2/en not_active Ceased
-
2010
- 2010-05-25 IL IL205949A patent/IL205949A/en active IP Right Grant
- 2010-06-11 CO CO10070802A patent/CO6300937A2/es not_active Application Discontinuation
-
2011
- 2011-12-19 US US13/330,363 patent/US8318765B2/en active Active
-
2012
- 2012-10-16 US US13/652,808 patent/US8492399B2/en active Active
-
2013
- 2013-06-19 US US13/921,448 patent/US8703791B2/en active Active
-
2014
- 2014-03-04 US US14/196,186 patent/US8969370B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072336A1 (es) | Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion | |
| AR046938A1 (es) | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| PH12018500106A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators | |
| AR064730A1 (es) | Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR068056A1 (es) | Derivados de n, n'-2, 4 - dianilinopirimidinas, su preparacion, su uso como medicamentos, composiciones farmaceuticas y especialmente como inhibidores de ikk. | |
| AR044829A1 (es) | Derivados de bis-4-cloro fenil pirazinas | |
| AR004972A1 (es) | Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado. | |
| AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| ES2531396T3 (es) | Proceso para preparar compuestos de piridinona | |
| AR059085A1 (es) | Derivados azufrados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de quinasas | |
| AR059086A1 (es) | Derivados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de cinasas | |
| AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| AR072820A1 (es) | Derivados de imidazo[1,2-a]pirimidina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| AR045859A1 (es) | Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos | |
| RS53903B1 (en) | ETHINYL DERIVATIVES AS POSITIVE MGLUR5 MODULATORS | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR041883A1 (es) | Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
| AR068467A1 (es) | Compuestos de nicotinamida sustituida y sus usos en medicamentos | |
| AR075160A1 (es) | Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos. | |
| AR072118A1 (es) | Derivados de pirrolidina como antagonistas de receptor de nk2 | |
| MY165141A (en) | Pyrazolidin-3-one derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |